AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34424743 — intervention group
Group type: EXPERIMENTAL
Intervention: Finishing with a bur (tungsten carbide, Reliance) with polishing with Sof‐Lex discs
Number of subjects: 125
Study 32883245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic cognitive training (CT)
Number of subjects: 200
Study 32883245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise training (ET)
Number of subjects: 200
Study 32883245 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive training + exercise training (CT + ET)
Number of subjects: 200
Study 32883245 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SC)
Number of subjects: 200
Study 35688618 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 591
Study 35688618 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-modifiable factors
Number of subjects: 591
Study 35688618 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifiable factors
Number of subjects: 591
Study 34165447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy (pool group)
Number of subjects: 115
Study 34165447 — intervention group
Group type: COMPARATOR
Intervention: Gym kinesitherapy (gym group)
Number of subjects: 115
Study 32866454 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-activation tools (3-minute video and 1-page checklist) delivered prior to cardiology clinic visits
Number of subjects: 305
Study 32866454 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 305
Study 35418868 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs for GERD
Number of subjects: 380218
Study 33214093 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (400 mg/kg, IV, daily for three days)
Number of subjects: 84
Study 33214093 — intervention group
Group type: COMPARATOR
Intervention: Control (hydroxychloroquine, lopinavir/ritonavir, and supportive care)
Number of subjects: 84
Study 33214093 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg initiation timing
Number of subjects: 84
Study 32660770 — intervention group
Group type: EXPERIMENTAL
Intervention: Plecanatide 3 mg
Number of subjects: 451
Study 32660770 — intervention group
Group type: EXPERIMENTAL
Intervention: Plecanatide 6 mg
Number of subjects: 451
Study 32660770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 35988343 — intervention group
Group type: EXPERIMENTAL
Intervention: Judo training program (120 min per week for three months)
Number of subjects: 57
Study 35988343 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 57
Study 34527921 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial exercise program twice a day for one month in addition to oral hygiene care advices (Group 1)
Number of subjects: 56
Study 34527921 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene care advices for the first month followed by orofacial exercise program for the next month (Group 2)
Number of subjects: 56
Study 32693858 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional education curriculum
Number of subjects: 2660
Study 32693858 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional education)
Number of subjects: 2660
Study 34818976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic compression (IC) + standard rehabilitation program (n=23)
Number of subjects: 46
Study 34818976 — intervention group
Group type: COMPARATOR
Intervention: Instrument-assisted soft tissue mobilization (IASTM) + standard rehabilitation program (n=23)
Number of subjects: 46
Study 36027955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3225
Study 36027955 — intervention group
Group type: EXPERIMENTAL
Intervention: Episiotomy
Number of subjects: 3225
Study 36027955 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps
Number of subjects: 3225
Study 36027955 — intervention group
Group type: EXPERIMENTAL
Intervention: Primiparity
Number of subjects: 3225
Study 36027955 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index 25-29.9 kg/m2
Number of subjects: 3225
Study 36027955 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index ≥30 kg/m2
Number of subjects: 3225
Study 33663478 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (six two-hour courses)
Number of subjects: 143
Study 33663478 — intervention group
Group type: COMPARATOR
Intervention: Control group (86 students)
Number of subjects: 143
Study 36047047 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation of hydroxychloroquine (200 mg tablet)
Number of subjects: 180
Study 36047047 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation of hydroxychloroquine (200 mg tablet)
Number of subjects: 180
Study 33549496 — intervention group
Group type: EXPERIMENTAL
Intervention: Research training and ongoing support for CPs
Number of subjects: 10
Study 32841937 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 180
Study 32841937 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide/Verapamil
Number of subjects: 180
Study 32841937 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 180
Study 33758067 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 102
Study 33758067 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (bed rest and orthosis)
Number of subjects: 102
Study 33590947 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management interventions
Number of subjects: 12
Study 32599274 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 64
Study 32599274 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 64
Study 35223743 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based after-school program (EXP)
Number of subjects: 59
Study 35223743 — intervention group
Group type: COMPARATOR
Intervention: Regular physical education (CON)
Number of subjects: 59
Study 33761729 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS‐CDS with a novel antimigration metal stent
Number of subjects: 95
Study 33761729 — intervention group
Group type: COMPARATOR
Intervention: ERCP with a traditional metal stent
Number of subjects: 95
Study 33761729 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS‐CDS
Number of subjects: 95
Study 34890069 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC‐NTF treatment
Number of subjects: 58
Study 34890069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 33561725 — intervention group
Group type: EXPERIMENTAL
Intervention: random noise stimulation (tRNS)
Number of subjects: 19
Study 33561725 — intervention group
Group type: COMPARATOR
Intervention: anodal transcranial direct current stimulation (tDCS)
Number of subjects: 19
Study 35876047 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation
Number of subjects: 1000
Study 35876047 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 1000
Study 35876047 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 1000
Study 34011040 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi Qi Capsules (BQC) in combination with Methotrexate
Number of subjects: 0
Study 34011040 — intervention group
Group type: COMPARATOR
Intervention: Control group (Methotrexate only)
Number of subjects: 0
Study 32403934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentraxin 3 (PTX3)
Number of subjects: 161
Study 32403934 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 6 (IL-6)
Number of subjects: 161
Study 32403934 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitive C-reactive protein (hs-CRP)
Number of subjects: 161
Study 35034763 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual surgical planning (experimental group)
Number of subjects: 50
Study 35034763 — intervention group
Group type: COMPARATOR
Intervention: Clinical experience (control group)
Number of subjects: 50
Study 32919894 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute non-therapeutic hand massage
Number of subjects: 138
Study 32919894 — intervention group
Group type: COMPARATOR
Intervention: Rest for 15 minutes (Control)
Number of subjects: 138
Study 35984434 — intervention group
Group type: EXPERIMENTAL
Intervention: Otoendoscopic tympanoplasty (OP)
Number of subjects: 76
Study 35984434 — intervention group
Group type: COMPARATOR
Intervention: Microscope tympanoplasty (MP)
Number of subjects: 76
Study 35467017 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil nut supplementation (1 Brazil nut per day for 3 months)
Number of subjects: 37
Study 35467017 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 37
Study 33762365 — intervention group
Group type: EXPERIMENTAL
Intervention: CT fractional flow reserve (CTFFR)
Number of subjects: 140
Study 33762365 — intervention group
Group type: COMPARATOR
Intervention: Direct ICA without functional test after CTCA
Number of subjects: 140
Study 32554646 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting mimicking diet (FMD) plus usual care
Number of subjects: 100
Study 32554646 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 100
Study 33883477 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) therapy based on intelligent wearable devices for 8 weeks
Number of subjects: 143
Study 33883477 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based modified behavioral activation (BA) therapy for 8 weeks
Number of subjects: 143
Study 33883477 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control group)
Number of subjects: 143
Study 32880490 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness Assurance Process (RAP) followed by Immediate Feedback from Faculty-Student Discussion (FSD) and Individual Application Exercises (iAE)
Number of subjects: 182
Study 32880490 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Readiness Assurance Test (iRAT) and Group Readiness Assurance Test (gRAT)
Number of subjects: 182
Study 32880490 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback during Faculty-Student Discussion (FSD) after gRAT
Number of subjects: 182
Study 33074423 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 81
Study 33074423 — intervention group
Group type: COMPARATOR
Intervention: Shock wave lithotripsy (SWL)
Number of subjects: 81
Study 36357960 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate)
Number of subjects: 477
Study 36357960 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy
Number of subjects: 477
Study 33621675 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS over PMdL during planning
Number of subjects: 20
Study 33621675 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS over PMdR during planning and execution
Number of subjects: 20
Study 32237291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragility Index (FI)
Number of subjects: 0
Study 35586186 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 50 mg single dose
Number of subjects: 36
Study 35586186 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 100 mg single dose
Number of subjects: 36
Study 35586186 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 150 mg single dose
Number of subjects: 36
Study 35586186 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib multiple doses (50, 100, 150 mg)
Number of subjects: 36
Study 35586186 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib multiple doses (higher dose groups)
Number of subjects: 36
Study 35586186 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib multiple doses (lower dose groups)
Number of subjects: 36
Study 34968124 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide prevention-focused group therapy
Number of subjects: 134
Study 34458930 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D/HD imaging technology
Number of subjects: 42
Study 34458930 — intervention group
Group type: COMPARATOR
Intervention: 2-D/4K imaging technology
Number of subjects: 42
Study 32948514 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-injected adrenaline (epinephrine) during food challenge
Number of subjects: 56
Study 34809904 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age at marriage
Number of subjects: 796
Study 34809904 — intervention group
Group type: COMPARATOR
Intervention: Control over decisions
Number of subjects: 796
Study 32000477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracuff lidocaine
Number of subjects: 3049
Study 32000477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 3049
Study 32000477 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine jelly
Number of subjects: 3049
Study 32000477 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine spray
Number of subjects: 3049
Study 36130275 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 145
Study 36130275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 34436928 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib 120 mg twice daily with carboplatin and paclitaxel
Number of subjects: 970
Study 34436928 — intervention group
Group type: COMPARATOR
Intervention: Placebo with carboplatin and paclitaxel
Number of subjects: 970
Study 34436928 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib in LP52-positive population
Number of subjects: 970
Study 34436928 — intervention group
Group type: COMPARATOR
Intervention: Placebo in LP52-positive population
Number of subjects: 970
Study 34436928 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib in LP52-negative population
Number of subjects: 970
Study 34436928 — intervention group
Group type: COMPARATOR
Intervention: Placebo in LP52-negative population
Number of subjects: 970
Study 34436928 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib with chemotherapy
Number of subjects: 970
Study 34436928 — intervention group
Group type: COMPARATOR
Intervention: Placebo with chemotherapy
Number of subjects: 970
Study 36029162 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic-efficacy-combination design
Number of subjects: 0
Study 36029162 — intervention group
Group type: COMPARATOR
Intervention: Alternative designs
Number of subjects: 0
Study 33616557 — intervention group
Group type: EXPERIMENTAL
Intervention: ID group (n = 20) with abutment preparations for inlay retainers (proximal box and occlusal extension)
Number of subjects: 30
Study 33616557 — intervention group
Group type: COMPARATOR
Intervention: PB group (n = 10) with only proximal box preparations
Number of subjects: 30
Study 33616557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 32915800 — intervention group
Group type: EXPERIMENTAL
Intervention: PGD symptoms and PGD diagnosis
Number of subjects: 852
Study 32915800 — intervention group
Group type: EXPERIMENTAL
Intervention: PGD symptoms and MDE diagnosis
Number of subjects: 852
Study 32915800 — intervention group
Group type: EXPERIMENTAL
Intervention: PGD symptoms and no diagnosis
Number of subjects: 852
Study 32915800 — intervention group
Group type: COMPARATOR
Intervention: No PGD symptoms and no diagnosis (integrated grief)
Number of subjects: 852
Study 32915800 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender of the bereaved (male vs female)
Number of subjects: 852
Study 36221155 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial TQL block
Number of subjects: 80
Study 33854404 — intervention group
Group type: COMPARATOR
Intervention: CHD group
Number of subjects: 49
Study 33854404 — intervention group
Group type: COMPARATOR
Intervention: HC group
Number of subjects: 49
Study 33854404 — intervention group
Group type: COMPARATOR
Intervention: CHD group and HC group
Number of subjects: 49
Study 32480364 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based prediction
Number of subjects: 151
Study 35982348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed appliances
Number of subjects: 135
Study 35982348 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable appliances
Number of subjects: 135
Study 35982348 — intervention group
Group type: COMPARATOR
Intervention: Control (teeth without trauma)
Number of subjects: 135
Study 34120912 — intervention group
Group type: EXPERIMENTAL
Intervention: Edasalonexent (100 mg/kg/day)
Number of subjects: 131
Study 34120912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 36255383 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ACPA IgA
Number of subjects: 97
Study 36255383 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ACPA IgG
Number of subjects: 97
Study 36255383 — intervention group
Group type: EXPERIMENTAL
Intervention: ACPA IgA and IgG levels
Number of subjects: 97
Study 32275468 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 100
Study 32275468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab
Number of subjects: 100
Study 33272980 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen (5 mg/day)
Number of subjects: 72
Study 33272980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 32131824 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal facilitators (IFs) with strong project management, team/process, and influencing/negotiating skills
Number of subjects: 9
Study 32131824 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior experience in project management and mental health background
Number of subjects: 9
Study 32131824 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal characteristics of IFs (e.g., flexible, assertive)
Number of subjects: 9
Study 32131824 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear delineation of EF/IF roles
Number of subjects: 9
Study 32131824 — intervention group
Group type: EXPERIMENTAL
Intervention: Shift of facilitation responsibilities to IFs
Number of subjects: 9
Study 35853716 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard urine chemistries
Number of subjects: 418
Study 35853716 — intervention group
Group type: EXPERIMENTAL
Intervention: NMR urine metabolites
Number of subjects: 418
Study 35853716 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model using urine chemistries and NMR-quantified metabolites
Number of subjects: 418
Study 33524985 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided percutaneous coronary intervention with implantation of a magnesium sirolimus-eluting Magmaris scaffold
Number of subjects: 0
Study 33524985 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided percutaneous coronary intervention with implantation of a magnesium sirolimus-eluting Magmaris scaffold
Number of subjects: 0
Study 35882511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ninjin'yoeito (NYT)
Number of subjects: 1066
Study 35882511 — intervention group
Group type: COMPARATOR
Intervention: Oral iron preparation
Number of subjects: 1066
Study 34289884 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly KBA training (n = 40)
Number of subjects: 120
Study 34289884 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly KBA training (n = 40)
Number of subjects: 120
Study 34289884 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (n = 40)
Number of subjects: 120
Study 34289884 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including KBA and control)
Number of subjects: 120
Study 35467561 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home blood pressure measurement protocol
Number of subjects: 0
Study 35467561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nourish trial intervention (Dietary Approaches to Stop Hypertension)
Number of subjects: 0
Study 35467561 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote visits due to COVID-19
Number of subjects: 0
Study 32402555 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg monthly
Number of subjects: 1097
Study 32402555 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg pro re nata (PRN) after 3 loading doses
Number of subjects: 1097
Study 32402555 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 2.0 mg monthly
Number of subjects: 1097
Study 32402555 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 2.0 mg PRN
Number of subjects: 1097
Study 32402555 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk factors for MA
Number of subjects: 1097
Study 35710044 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal combos (low-calorie default items)
Number of subjects: 636
Study 35710044 — intervention group
Group type: COMPARATOR
Intervention: Traditional combos (high-calorie default items)
Number of subjects: 636
Study 35710044 — intervention group
Group type: COMPARATOR
Intervention: Choice combos (create-your-own combo)
Number of subjects: 636
Study 35710044 — intervention group
Group type: COMPARATOR
Intervention: Photos (visual cues)
Number of subjects: 636
Study 34162645 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week open-label placebo treatment
Number of subjects: 0
Study 32216840 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home intervention program over 4 months consisting of six home visits and two telephone contacts with a rehabilitation professional.
Number of subjects: 120
Study 32216840 — intervention group
Group type: COMPARATOR
Intervention: Standard care in the municipalities (control group).
Number of subjects: 120
Study 32213291 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 12.5 mg every 12 hours
Number of subjects: 71
Study 32213291 — intervention group
Group type: COMPARATOR
Intervention: No pharmacologic prophylaxis
Number of subjects: 71
Study 32311001 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative performance information feedback
Number of subjects: 0
Study 32311001 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34166959 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led educational intervention on inhalation technique education via demonstration and repetition
Number of subjects: 201
Study 32010994 — intervention group
Group type: EXPERIMENTAL
Intervention: New predictive equations for estimating resting energy expenditure (REE)
Number of subjects: 270